Chronic Diseases Drive 40% of India Pharma Market
India’s pharmaceutical market continued its strong growth trajectory in March 2026, expanding 10.7% year-on-year, driven largely by rising demand for treatments targeting chronic conditions. According to data from IQVIA and Equirus Securities, diseases such as hypertension, diabetes and high cholesterol now account for over 40% of the total market, reflecting a steady shift toward long-term therapies.
Cardiac treatments remained the largest segment, contributing nearly 14% of overall sales and growing 14.9% in March, while anti-diabetic therapies rose 14.2%. Increased prescriptions, improved pricing, and new product launches have all contributed to growth, marking one of the strongest performance periods in recent quarters. Chronic therapies are also outpacing acute treatments, highlighting changing healthcare needs in India.
Competition is intensifying in the diabetes segment following the patent expiry of semaglutide, a key ingredient in drugs like Ozempic by Novo Nordisk. Several companies have launched branded generics at lower prices, reshaping the market landscape. While firms like Dr. Reddy’s Laboratories and Sun Pharmaceutical Industries posted strong growth, others faced pressure amid rising competition and shifting demand patterns.
Pic courtesy: google/ images are subject to copyright
